Dr. Himanshu Narayan Singh | Genetics and Molecular Biology | Best Researcher Award

Sr. Research Scientist at Memorial Sloan Kettering Cancer Center, United States

Dr. Himanshu Narayan Singh is an accomplished cancer biologist and functional genomics researcher with an extensive international academic and research background. Currently serving as a Research Fellow at Memorial Sloan Kettering Cancer Center (MSKCC), New York, USA, and RF-PostDoc under the CUNY-MSKCC Partnership Program, his research focuses on the treatment-driven evolution of high-grade tumors. His work emphasizes understanding the interplay between tumor microenvironment and disease progression in response to diverse therapeutic interventions. With over a decade of research experience, Dr. Singh has made significant contributions to cancer biology, functional genomics, and systems biology through his positions at prestigious institutions worldwide.

Profile

Scholar

Education:

Dr. Singh’s academic journey reflects his multidisciplinary expertise. He earned his Bachelor of Technology in Biotechnology from IASE Deemed University, Rajasthan, India, in 2008, followed by a Master of Technology in Bioinformatics from Jamia Hamdard University, New Delhi, in 2011. He completed his Ph.D. in Genomics and Bioinformatics from Noida International University (2013-2016), while conducting research at the CSIR-Institute of Genomics & Integrative Biology and the All India Institute of Medical Sciences (AIIMS), New Delhi. Postdoctoral training took him across premier research institutes: molecular medicine at CSIR-IGIB (2016-2018), functional genomics at INSERM & Aix Marseille University, France (2018-2021), and systems biology at Columbia University, USA (2021-2022), culminating in his current role at MSKCC (2022 onwards).

Experience:

Dr. Singh’s professional trajectory showcases a progressive ascent through various research roles. He began as a Research Fellow and Senior Research Fellow at AIIMS, New Delhi (2011-2016), transitioned to Research Associate at CSIR-IGIB (2016-2018), and advanced to Postdoctoral Fellow at Aix Marseille University, France (2018-2021). His subsequent appointment at Columbia University as Postdoctoral Research Scientist further refined his expertise in regulatory network analysis. Since 2022, he has been contributing as Senior Research Scientist and now as Research Fellow at MSKCC, New York, focusing on tumor evolution and cancer biology. His extensive computational and wet-lab experience includes CNV/variant calling, tumor phylogenetics, RNA-seq, ChIP-seq, and molecular dynamics simulations.

Research Interest:

Dr. Singh’s research centers on understanding how high-grade tumors evolve under therapeutic pressures, with an emphasis on deciphering tumor microenvironmental changes and regulatory network disruptions. His work integrates cutting-edge bioinformatics tools and next-generation sequencing approaches to study tumor heterogeneity, cancer epigenomics, and systems-level alterations during disease progression. Notably, he developed an innovative pipeline for identifying epromoters during his tenure in France, which garnered significant attention with a publication in Nature Communications. His interests also span molecular medicine, epigenomics, bioinformatics software development, and the application of deep learning for cancer prognosis.

Awards:

Dr. Singh has received numerous accolades recognizing his scientific contributions. Highlights include the Young Scientist Award (INSO Awards 2022, India), Best Oral Presentation Award at the International Congress on Friedreich’s Ataxia and DNA Structure in Health & Disease (AIIMS, 2015), and 16 international travel grants from prestigious organizations such as ICMR, DST, DBT, and multiple international societies. He was twice invited as a Researcher under the DST-WTZ Indo-Austria Project at the Medical University of Vienna. Additionally, he secured two independent research project grants: one from the Indian Council of Medical Research and another from the Druckenmiller Center for Lung Cancer Research, MSKCC.

Publication:

Dr. Singh has an impressive publication record with around 45 articles and over 35 abstracts. Selected key publications include:

1. Chunarkar-Patil P, et al., Singh HN*, Kumar S*. “Anticancer Drug Discovery Based on Natural Products.” Biomedicines, 2024; 12(1):201. IF 4.7. Cited by: 5.
2. Singh Y, Subbarao N, Singh HN*. “Genome-wide expression reveals potential biomarkers in breast cancer bone metastasis.” J Integr Bioinform., 2022. IF 3.321. Cited by: 7.
3. Santiago-Algarra D, Singh H, et al. “Epromoters function as a hub to recruit transcription factors.” Nat Commun., 2021; 12:6660. IF 14.92. Cited by: 18.
4. Musini A, Singh HN. “Quercetin’s antibiofilm effectiveness against drug resistant Staphylococcus aureus.” Res Microbiol., 2023. IF 3.94. Cited by: 3.
5. Kumar S, Singh HN*, et al. “Transcriptomic Profiling Unravels Novel Deregulated Gene Signatures.” Genes, 2022; 13(12):2321. IF 4.14. Cited by: 4.
6. Singh HN, Rajeswari MR*. “DNA-triplex Forming Purine Repeat Containing Genes.” Front Cell Infect Microbiol., 2017; 7:250. IF 5.29. Cited by: 10.
7. Singh HN, Rajeswari MR*. “nTrackAnnotator: Software for detection and annotation.” Gene Reports, 2017; 7:32-34. IF 0.72. Cited by: 6.

Conclusion:

Dr. Himanshu Narayan Singh exemplifies excellence in interdisciplinary biomedical research, seamlessly integrating computational biology, functional genomics, and cancer medicine. His trajectory reflects not only scientific rigor but also a commitment to innovation, global collaboration, and translational impact. His leadership in cancer research, multiple high-impact publications, significant grant acquisitions, and numerous international honors underscore his suitability for prestigious research awards. Dr. Singh continues to advance the frontiers of cancer biology, contributing valuable insights into tumor evolution and therapeutic response mechanisms that hold promise for improving cancer treatment outcomes globally.